PolyPid Ltd. (PYPD) is an Israeli clinical-stage biopharmaceutical company developing long-acting, locally delivered therapies. Its lead candidate, D-PLEX100, targets prevention of surgical site infections (SSIs) following abdominal colorectal surgery.
Four current analyst price targets were reviewed: H.C. Wainwright at $13 (Buy, November 12, 2026), Craig-Hallum at $12 (Buy, July 22, 2026), Oppenheimer at $10 (Outperform, initiated October 27, 2026), and Roth MKM at $8.50 (Buy, November 12, 2026). Their average is approximately $10.88, rounded to a central target of $11, with a wide low-to-high range of $8.50 to $13.
The spread reflects genuine disagreement. Bulls such as H.C. Wainwright weight the size of the addressable market and the Azurity partnership, while more cautious firms such as Roth MKM apply lower probability to regulatory and commercial execution. All four ratings are positive, but the roughly 53% gap between the lowest and highest target signals real uncertainty about a pre-revenue biotech.
As of its most recent close, PYPD traded around $6.15, within a 52-week range of $3.50 to $7.15. Reaching $11 implies upside of about 79%, which is a very large move. The path depends primarily on binary regulatory events rather than steady earnings growth, because the company generates no meaningful revenue and posted a net loss of $7.8 million in the second quarter of 2026.
The nearest catalyst is the November 28, 2026 PDUFA (Prescription Drug User Fee Act) goal date for D-PLEX100, which was accepted for priority review. Approval would shift the debate to launch execution, while a delay or rejection would likely remove the central basis for current valuations. A U.S. launch is targeted for early 2027, with reimbursement clarity not expected until an NTAP decision in August 2027.
D-PLEX100 met its primary endpoint and a key secondary endpoint in the Phase 3 SHIELD II trial, showing a 60% relative risk reduction in SSI incidence. The FDA accepted the NDA (New Drug Application) with priority review, and a Marketing Authorization Application was validated by the European Medicines Agency in September 2026.
The July 2026 Azurity agreement provides $30 million in upfront and near-term payments, eligibility for more than $290 million in additional milestones, and tiered royalties in the mid-teens to mid-twenties percent range. Management believes current resources, including these payments, fund operations into 2028. Label expansion into broader abdominal surgery represents a meaningful optional opportunity beyond the initial indication.
The most immediate risk is regulatory: approval is not guaranteed, and the outcome of the FDA pre-approval manufacturing inspection has not been disclosed. A Complete Response Letter or approval delay could materially reset the stock.
Beyond approval, adoption is expected to be a gradual, account-by-account hospital formulary process. Pricing has not been disclosed and rests with Azurity, creating uncertainty around the economic case for hospitals. Reimbursement via NTAP, which could cover up to 75% of product cost, is not decided until August 2027. The company also remains deeply unprofitable, with cash of $6.6 million at mid-2026 before milestone receipts, and is highly concentrated on a single product.
PYPD has rallied sharply over the past year, climbing from a 52-week low near $3.50 toward a 52-week high of $7.15. The $7.00-to-$7.15 zone represents recent resistance that the stock must clear before a move toward double digits becomes a technical reality. A round-number area near $10-to-$11 sits well above any recent trading range and has no established support from current price action, underscoring how dependent the target is on positive news flow rather than chart structure.
Analyst price targets generally reflect a roughly 12-month research horizon, though firms do not always disclose a precise timeframe. The nearest items to watch are the November 28, 2026 PDUFA decision, any FDA pre-approval inspection updates, early 2027 launch execution and pricing disclosure, the August 2027 NTAP reimbursement decision, and the European Medicines Agency review expected in the second half of 2027. Quarterly earnings and cash runway commentary also remain important given the company's pre-revenue status.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals from shifting market conditions, technical behavior, and AI-driven analysis. For a volatile name like PYPD, where sentiment can turn quickly around a single regulatory headline, such tools can help traders discover opportunities, monitor existing positions, and spot changing trends more efficiently than manual screening alone.
Can PolyPid reach $11? The central $11 figure is the average of four recent analyst targets, not a forecast of what will happen. It sits roughly 79% above the current price, making it a demanding objective that hinges on FDA approval, a successful early 2027 launch, and continued execution by Azurity. The bullish case is grounded in positive Phase 3 data, priority review, and a validated commercial partner; the bear case points to binary regulatory risk, a gradual hospital adoption curve, unresolved pricing, and a single-product, pre-revenue profile. The wide $8.50-to-$13 analyst range captures that genuine uncertainty. Investors should treat the November 28 PDUFA decision as the pivotal near-term event, with launch execution and reimbursement timing shaping whether the stock can close even part of the gap toward double digits.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor tells us that PYPD and BCYC have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that PYPD and BCYC's prices will move in lockstep.
| Ticker / NAME | Correlation To PYPD | 1D Price Change % | ||
|---|---|---|---|---|
| PYPD | 100% | +6.34% | ||
| BCYC - PYPD | 31% Poorly correlated | +0.63% | ||
| TSHA - PYPD | 31% Poorly correlated | -1.48% | ||
| IDYA - PYPD | 29% Poorly correlated | -9.75% | ||
| AMLX - PYPD | 29% Poorly correlated | -1.01% | ||
| SYRE - PYPD | 29% Poorly correlated | -5.60% | ||
More | ||||